These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 26497595)

  • 21. Evaluation of vancomycin population susceptibility analysis profile as a predictor of outcomes for patients with infective endocarditis due to methicillin-resistant Staphylococcus aureus.
    Casapao AM; Davis SL; McRoberts JP; Lagnf AM; Patel S; Kullar R; Levine DP; Rybak MJ
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4636-41. PubMed ID: 24890596
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia.
    Maor Y; Hagin M; Belausov N; Keller N; Ben-David D; Rahav G
    J Infect Dis; 2009 Mar; 199(5):619-24. PubMed ID: 19199552
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the clinical features, bacterial genotypes and outcomes of patients with bacteraemia due to heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-susceptible S. aureus.
    Park KH; Kim ES; Kim HS; Park SJ; Bang KM; Park HJ; Park SY; Moon SM; Chong YP; Kim SH; Lee SO; Choi SH; Jeong JY; Kim MN; Woo JH; Kim YS
    J Antimicrob Chemother; 2012 Aug; 67(8):1843-9. PubMed ID: 22535621
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence and Clinical Impact of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolated From Hospitalized Patients.
    Koh YR; Kim KH; Chang CL; Yi J
    Ann Lab Med; 2016 May; 36(3):235-43. PubMed ID: 26915612
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections.
    Claeys KC; Zasowski EJ; Casapao AM; Lagnf AM; Nagel JL; Nguyen CT; Hallesy JA; Compton MT; Kaye KS; Levine DP; Davis SL; Rybak MJ
    Antimicrob Agents Chemother; 2016 Oct; 60(10):5841-8. PubMed ID: 27431221
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Etest Methods for Screening Heterogeneous Vancomycin-Intermediate Staphylococcus aureus (hVISA) strains.
    Lee MY; Lee WI; Kim MH; Kang SY; Kim YJ
    Curr Microbiol; 2020 Oct; 77(10):3158-3167. PubMed ID: 32734419
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection of heterogeneous vancomycin-intermediate
    Amberpet R; Sistla S; Sugumar M; Nagasundaram N; Manoharan M; Parija SC
    Indian J Med Res; 2019 Aug; 150(2):194-198. PubMed ID: 31670275
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance.
    Bae IG; Federspiel JJ; Miró JM; Woods CW; Park L; Rybak MJ; Rude TH; Bradley S; Bukovski S; de la Maria CG; Kanj SS; Korman TM; Marco F; Murdoch DR; Plesiat P; Rodriguez-Creixems M; Reinbott P; Steed L; Tattevin P; Tripodi MF; Newton KL; Corey GR; Fowler VG;
    J Infect Dis; 2009 Nov; 200(9):1355-66. PubMed ID: 19811099
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship between day 1 and day 2 Vancomycin area under the curve values and emergence of heterogeneous Vancomycin-intermediate Staphylococcus aureus (hVISA) by Etest® macromethod among patients with MRSA bloodstream infections: a pilot study.
    Martirosov DM; Bidell MR; Pai MP; Scheetz MH; Rosenkranz SL; Faragon C; Malik M; Mendes RE; Jones RN; McNutt LA; Lodise TP
    BMC Infect Dis; 2017 Aug; 17(1):534. PubMed ID: 28764660
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia.
    Howden BP; Johnson PD; Ward PB; Stinear TP; Davies JK
    Antimicrob Agents Chemother; 2006 Sep; 50(9):3039-47. PubMed ID: 16940100
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular characteristics and virulence factors in methicillin-susceptible, resistant, and heterogeneous vancomycin-intermediate Staphylococcus aureus from central-southern China.
    Liu C; Chen ZJ; Sun Z; Feng X; Zou M; Cao W; Wang S; Zeng J; Wang Y; Sun M
    J Microbiol Immunol Infect; 2015 Oct; 48(5):490-6. PubMed ID: 24767415
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Evaluation of methicillin-resistant Staphylococcus aureus bacteremia and comparison of prognosis according to vancomycin MIC values: experience of the last ten years].
    Kızılarslanoğlu MC; Sancak B; Yağcı S; Hasçelik G; Unal S
    Mikrobiyol Bul; 2013 Apr; 47(2):199-210. PubMed ID: 23621720
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence and Microbiological Characteristics of qacA/B-Positive Methicillin-Resistant Staphylococcus aureus Isolates in a Surgical Intensive Care Unit.
    Cho OH; Park KH; Song JY; Hong JM; Kim T; Hong SI; Kim S; Bae IG
    Microb Drug Resist; 2018 Apr; 24(3):283-289. PubMed ID: 28799881
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early response assessment to guide management of methicillin-resistant Staphylococcus aureus bloodstream infections with vancomycin therapy.
    Joo J; Yamaki J; Lou M; Hshieh S; Chu T; Shriner KA; Wong-Beringer A
    Clin Ther; 2013 Jul; 35(7):995-1004. PubMed ID: 23829982
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of methicillin-resistant Staphylococcus aureus (MRSA) infection and the molecular characteristics of MRSA bacteraemia over a two-year period in a tertiary teaching hospital in Malaysia.
    Sit PS; Teh CS; Idris N; Sam IC; Syed Omar SF; Sulaiman H; Thong KL; Kamarulzaman A; Ponnampalavanar S
    BMC Infect Dis; 2017 Apr; 17(1):274. PubMed ID: 28407796
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vivo development of daptomycin resistance in vancomycin-susceptible methicillin-resistant Staphylococcus aureus severe infections previously treated with glycopeptides.
    Capone A; Cafiso V; Campanile F; Parisi G; Mariani B; Petrosillo N; Stefani S
    Eur J Clin Microbiol Infect Dis; 2016 Apr; 35(4):625-31. PubMed ID: 26815434
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular Epidemiology and Virulence Features of Staphylococcus aureus Bloodstream Isolates in a Regional Burn Center in China, 2012-2016.
    Liu Y; Du FL; Liu PP; Mei YF; Wan LG; Wei DD; Xu HY; Zhang W
    Microb Drug Resist; 2018 Nov; 24(9):1354-1360. PubMed ID: 29565724
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Case-control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2 microg/mL and risk factors, costs, and outcomes in inpatients undergoing hemodialysis.
    Maclayton DO; Suda KJ; Coval KA; York CB; Garey KW
    Clin Ther; 2006 Aug; 28(8):1208-1216. PubMed ID: 16982298
    [TBL] [Abstract][Full Text] [Related]  

  • 39. agr functionality affects clinical outcomes in patients with persistent methicillin-resistant Staphylococcus aureus bacteraemia.
    Kang CK; Kim YK; Jung SI; Park WB; Song KH; Park KH; Choe PG; Jang HC; Lee S; Kim YS; Kwak YG; Kwon KT; Kiem S; Kim CJ; Kim ES; Kim HB;
    Eur J Clin Microbiol Infect Dis; 2017 Nov; 36(11):2187-2191. PubMed ID: 28639163
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative proteomics-based identification of genes associated with glycopeptide resistance in clinically derived heterogeneous vancomycin-intermediate Staphylococcus aureus strains.
    Chen H; Liu Y; Zhao C; Xiao D; Zhang J; Zhang F; Chen M; Wang H
    PLoS One; 2013; 8(6):e66880. PubMed ID: 23840544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.